What you should know:
1. Naia is developing a short bowel syndrome treatment and has other GI drugs in the pipeline.
2. RDD Pharma expects to close the deal after its merger with Innovate Biopharmaceuticals closes, forming 9 Meters Biopharma.
3. Naia will receive a combination of cash and shares in 9 Meters Biopharma if both deals close.
More articles on surgery centers:
CMS to pay for total knees in ASCs, boost ASC payment rate 2.6% in 2020: 4 details
With $60B+ deals this year, what’s in store for private equity in the future?
Texas health system building ASC — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.